Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

pectively. The weighted average shares used in computing loss per share attributable to common stockholders exclude anti-dilutive securities such as stock options and warrants.

Cash, cash equivalents and short-term investments were approximately $30.8 million as of September 30, 2008, compared to $38.0 million at June 30, 2008.

Stephen Ghiglieri, CFO, commented, "In this difficult financial market, we are dedicating our financial resources primarily to obtain marketing approvals for NGX-4010. By pursuing this focused strategy, we believe our existing cash resources are sufficient to move us through expected regulatory decisions in both the U.S. and Europe, and potentially into early 2010. Our objective is to ensure an effective launch of NGX-4010, if approved, in both Europe and the United States. We intend to achieve this through effective cost management, including a near-term focus on activities for NGX-4010 that support the ongoing regulatory review processes and our reimbursement strategies and through commercial partnerships and other non-equity sources of funding. In addition, we anticipate that these other sources of funding could create opportunities to more rapidly advance our development initiatives in addition to effectively launching NGX-4010 in the United States. Given the current state of the equity markets, we have no current intention to raise equity capital in the public markets."

Clinical Development Update

NeurogesX' near-term clinical focus is to secure regulatory approvals of the NDA and MAA for NGX-4010. Regarding the potential for additional clinical studies in HIV-DSP and/or PDN, NeurogesX continues to evaluate the appropriate scope and nature of future studies, if any, in these indications. The timing for initiating such studies will be based in part on availability of financial resources.

NGX-1998, the Company's second-generation, liquid formulation of high-concentration capsaicin (10% trans-capsaicin) is
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... An interdisciplinary team of researchers led by Northeastern ... constructing precise inter-nanotube junctions and a variety of ... is facile and easily scalable, which will allow ... nanotube networks for use in applications ranging from ... everything from cars to sports equipment. , Their ...
(Date:9/15/2014)... 2014 Zymo Research Corp., has announced the ... safe ambient temperature storage and transport of infectious ... of agents in such samples is completely inactivated ... the viral nucleic acids for subsequent analyses.  With ... in West Africa and ...
(Date:9/15/2014)... Research and Markets has announced the addition of ... by Technology, by Application - Global Forecast to 2018" ... (WES) is next-generation technology used for strategically sequencing the coding ... is the total of all exons of an organism, represents ... into proteins after translation. It is responsible for the occurrence ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
Breaking Biology Technology:Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2
... , a provider of managed network security services, said ... assets of Mycom's mailMAX Managed Services Division ... Group, Inc. , ,SecurePipe is a provider of managed ... health care and financial institutions. Headquarted in Illinois, about ...
... we reviewed the performance of the Midwest large cap life science group ... reacted during the first half of 2005. , ,The message was that ... below) with the exception of the Amex Biotech index. In spite of ... a very solid basis. , , , ,For this week, ...
... Time Warner Cable and Charter ... would partner to provide businesses in their service areas ... Cable Business Class Services and Charter Business ... area businesses with high-speed Optical Ethernet service. , ,The ...
Cached Biology Technology:Midwest biotech stocks receive hefty haircut in first half of 2005 2Charter and Time Warner to partner on fiber optics 2
(Date:9/15/2014)... as much as 170 tons, the blue whale is the ... living thing ever seen on Earth. So there,s no way ... larvae, which measure millimeters in length and tip the scales ... so fast, says L. Mahadevan, the Lola England de Valpine ... of Physics. , Using simple hydrodynamics, a team of ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  GENiSYSS, ... California , announces the public launch of ... very unique, patented product, combining room temperature, long-term ... the only company to make personal storage of ... Photo - http://photos.prnewswire.com/prnh/20140912/145664   Photo - ...
Breaking Biology News(10 mins):The science behind swimming 2The science behind swimming 3GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone 2
... Two scientists are challenging the currently accepted norms of ... Bioenergy reveals that calculations of greenhouse gas (GHGs) ... has led to the overestimation of the benefits of ... extends to the Life Cycle Analysis models of bioenergy ...
... 2012), the world,s leading coral reef science conference held ... in Cairns, Queensland, Australia. The symposium will bring together ... present the latest findings on coral reef science and ... the symposium, daily media briefings will be held for ...
... , A team of researchers, including scientists from Woods ... phytoplankton beneath ice-covered Arctic waters. Until now, sea ice ... of microscopic marine plants living under the ice. ... was four times greater than the amount found in ...
Cached Biology News:Environmental benefit of biofuels is overestimated, new study reveals 2Coral reef experts to present latest coral reef science during July symposium 2Coral reef experts to present latest coral reef science during July symposium 3Scientists discover huge phytoplankton bloom in ice-covered waters 2Scientists discover huge phytoplankton bloom in ice-covered waters 3
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
in vitro Translation, Accessory Products...
... SAGE (serial analysis of ... genome-wide expression analysis. Expression profiles ... enough to detect low-abundance transcripts ... novel genes. The I-SAGE Kit ...
Sheep Serum US Origin...
Biology Products: